Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Development and validation of risk models and molecular diagnostics to permit personalized management of cancer.

Authors
Type
Published Article
Journal
Cancer
1097-0142
Publisher
Wiley Blackwell (John Wiley & Sons)
Publication Date
Volume
120
Issue
1
Pages
11–19
Identifiers
DOI: 10.1002/cncr.28393
PMID: 24114238
Source
Medline
Keywords
License
Unknown

Abstract

Despite the advances made in cancer management over the past few decades, improvements in cancer diagnosis and prognosis are still poor, highlighting the need for individualized strategies. Toward this goal, risk prediction models and molecular diagnostic tools have been developed, tailoring each step of risk assessment from diagnosis to treatment and clinical outcomes based on the individual's clinical, epidemiological, and molecular profiles. These approaches hold increasing promise for delivering a new paradigm to maximize the efficiency of cancer surveillance and efficacy of treatment. However, they require stringent study design, methodology development, comprehensive assessment of biomarkers and risk factors, and extensive validation to ensure their overall usefulness for clinical translation. In the current study, the authors conducted a systematic review using breast cancer as an example and provide general guidelines for risk prediction models and molecular diagnostic tools, including development, assessment, and validation.

Statistics

Seen <100 times